Viruses
Nirmatrelvir/Ritonavir Versus Remdesivir Therapy for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Kidney Transplant Recipients: A Retrospective Study
By Nasser I Alrubayan, Aziza A. Ajlan, Edward Bentz Devol and 7 others.
Abstract
Background
The prognosis of coronavirus disease-2019 (COVID-19) in solid organ transplant recipients is extremely poor. The efficacy and safety of various treatments used in COVID-19 have not been fully explored in kidney transplant recipients (KTRs). This study aims to investigate the safety and efficacy of nirmatrelvir/ritonavir versus remdesivir in adult KTRs infected with COVID-19.
Methods
This single-center, retrospective, comparative study, conducted at a tertiary care hospital, enrolled adult KTRs with polymerase chain reaction-confirmed COVID-19 infection receiving nirmatrelvir/ritonavir or remdesivir from April 2021 to October 2023. The primary endpoint was the percentage of participants with COVID-19-related hospitalization within 28 days post-treatment completion. Secondary endpoints included graft rejection, patient and graft survival, worsening COVID-19 stage, and drug–drug interactions.